论文部分内容阅读
应用HA方案（三尖杉酯硷联合阿糖胞苷）剂量个体化治疗23例老年人慢性粒细胞白血病（慢粒），完全缓解（CR）率为69．6％，CR平均所需15．4天，平均持续CR时间为34.3月，均显著高于单用马利兰／羟基脲组；骨髓抑制发生率为34.8％，但经间歇期后均恢复正常．bcr／ablmRNA阳性病例的CR率为85．7％（12／14）优于bcr／ablmRNA阴性病例（0／3）．本资料显示：HA方案剂量个体化治疗老年人慢粒缓解率高，CR所需时间短，维持CR时间长，副作用小，是老年人慢粒治疗较满意方案．
Twenty-three elderly patients with chronic myeloid leukemia (CML) were treated with the HA regimen (harringtonine combined with cytarabine) in a dose-specific manner. The complete remission (CR) rate was 69.6%, and the mean CR was 15. At 4 days, the average duration of CR was 34.3 months, which was significantly higher than that of the single use of the maleic acid/hydroxyurea group. The incidence of myelosuppression was 34.8%, but it returned to normal after the intermittent period. The CR rate of bcr/abl mRNA positive cases was 85.7% (12/14) better than bcr/abl mRNA negative cases (0/3). The data show that: HA regimen individualized treatment of elderly patients with high rate of chronic remission, CR requires a short time, to maintain a long CR time, side effects, is a more satisfactory program for the treatment of chronic granules in the elderly.